Skip to main content

AI Bias Analysis

4 models · Takes ~15 seconds

Stat News

STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B

STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
ShareXFacebook

GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.

S

Source

Stat News

Read full article at Stat News

Opens original article in a new tab

Advertisement

Related Health Stories

Advertisement